Skip to content

Panitumumab fixed nonlinear PK

Two fixed published coefficient vectors for apparent two-compartment panitumumab disposition with parallel linear and saturable elimination, separate drug-loss accounting and serum exposure.

Analysis of the relationship between body composition and the pharmacokinetics of panitumumab in the treatment of localized squamous cell carcinoma of the anus – An ancillary study of the FFCD0904 phase I and II trial ↗

Biomedicine & Pharmacotherapy

Exploration notes · What are you exploring?

Notes stay on this browser.

MODEL IN MOTION 18 sec

How does repeated panitumumab dosing build central amount and exposure?

Run settings

Run location

Explore this model

Choose a scenario, adjust inputs, and run the simulation.

Final Table 2 fixed PK vector

Fixed published final coefficient vector; 186mg authored bolus approximation; not a population or individual prediction

0–70 day

Scenario details

Final Table 2 fixed PK vector

Fixed published final coefficient vector; 186mg authored bolus approximation; not a population or individual prediction

Readouts

Central conc · mg/L
Serum central amount divided by apparent central volume
Exposure (AUC) · mg*day/L
Nonfeedback exposure, clock or integrated elimination coordinate
Accounted drug · mg
Current plus integrated eliminated drug; equals cumulative delivered mg
Linear elimination · mg/day
Concentration-proportional elimination flux
Michaelis menten elimination · mg/day
Phenomenological saturable elimination flux; no receptor occupancy state

Study purpose

  • How do the model's key biological readouts change under final table 2 fixed pk vector?

Assumptions

  • Interpret patterns within this model and starting configuration; do not treat them as clinical predictions or treatment recommendations.

Inputs changed since the displayed result. Run to update the comparison.

Loading starting example…

Edit inputs

Simulation time
day
day
70 → 168

Time between reported samples.

day
0.25 → 1

2 changes · Variation 1

Continue in the background and keep the result.

Biology

Two fixed published coefficient vectors for apparent two-compartment panitumumab disposition with parallel linear and saturable elimination, separate drug-loss accounting and serum exposure.

Two fixed published coefficient vectors for apparent two-compartment panitumumab disposition with parallel linear and saturable elimination, separate drug-loss accounting and serum exposure.

Model details

6 parameters · 6 states · 6 equations · 21 derived outputs

Classification & API access
Therapeutic
Panitumumab
Modality
Monoclonal antibody
Target
EGFR / ERBB1
Disease / scope
Cancer therapy with EGFR-targeted panitumumab
ParameterDefaultUnitDescription
Systemic clearancecl_l_day0.4L/dayFixed published coefficient for the selected final or initial structural PK context; no editable or population-fitting domain.
Kmkm_mg_l0.112mg/LFixed published coefficient for the selected final or initial structural PK context; no editable or population-fitting domain.
Intercompartmental clearanceq_l_day0.17L/dayFixed published coefficient for the selected final or initial structural PK context; no editable or population-fitting domain.
Central distribution volumev1_l2.51LFixed published coefficient for the selected final or initial structural PK context; no editable or population-fitting domain.
Peripheral distribution volumev2_l2.91LFixed published coefficient for the selected final or initial structural PK context; no editable or population-fitting domain.
Maximum elimination ratevmax_mg_day4.26mg/dayFixed published coefficient for the selected final or initial structural PK context; no editable or population-fitting domain.

Related models

T-DM1 and T-DXd conditional intact-ADC pharmacokineticsDupilumab exposure and atopic-dermatitis responseAZD7442 total-antibody pharmacokineticsEnvafolimab subcutaneous population PK

Feedback: helpdesk@unibiointelligence.com.

Ubi Biologics